Four biotechs spanning a diverse set of therapy targets are seeking out nearly $400 million in a series of IPOs announced just before the New Year.
Dermatology biotech Menlo Therapeutics is looking to take advantage of the strong IPO window with a $98 million offering.
Next year will be a busy time for the European Medicines Agency as it looks to complete its move to Amsterdam.
While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.
If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.
At the end of the year, we all like to navel gaze, and editors are no different. It's a good time to reflect on what we write about, the importance of…
Will this year’s resurgence be sustained in 2018 in the face of a more uncertain environment?
Breakout Labs has backed over 30 companies since it handed out the first batch of grants in 2012.
FLX Bio has boosted its cash supplies with a new $60 million series C round as it starts dosing for its first cancer test.
Tessa Therapeutics raised $80 million in a financing round that will usher its virus-specific T cell immunotherapies through clinical trials.